GSK's $100M ADC bet in doubt after fatality in first trial of Mersana's cancer therapy March 13, 2023 4:59 am https://www.fiercebiotech.com/biotech/gsks-100m-adc-bet-doubt-after-fatality-first-trial-mersanas-therapy

UK biopharma body praises bank for keeping doors open at life science startups by rescuing SVB UK March 13, 2023 3:11 am https://www.fiercebiotech.com/biotech/governments-biotechs-scramble-contain-svb-fallout

After slimming down, Applied Molecular Transport no closer to taking UC drug into phase 3 March 10, 2023 6:34 am https://www.fiercebiotech.com/biotech/after-slimming-down-applied-molecular-transport-no-closer-taking-uc-drug-phase-3

FDA placed hold on Fulcrum's sickle cell therapy over hematological malignancy concerns March 9, 2023 6:03 am https://www.fiercebiotech.com/biotech/fda-placed-hold-fulcrums-sickle-cell-therapy-over-hematological-malignancy-concerns

All systems go for Mesoblast’s 2nd attempt to secure allogeneic cell therapy FDA win March 8, 2023 6:11 am https://www.fiercebiotech.com/biotech/all-systems-go-mesoblasts-2nd-attempt-secure-allogeneic-cell-therapy-fda-win

Fresh Tracks may disappear as biotech mulls sale to continue autoimmune pipeline March 8, 2023 5:42 am https://www.fiercebiotech.com/biotech/fresh-tracks-may-disappear-biotech-mulls-sale-continue-autoimmune-pipeline

Third Rock, J&J spinout Rapport arrives with $100M and ambition to transform precision neuroscience March 7, 2023 4:27 am https://www.fiercebiotech.com/biotech/third-rock-jj-spinout-rapport-arrives-100m-and-ambition-transform-precision-neuroscience

2 months after depression fail, Atai lays off 30% and reviews pipeline again March 6, 2023 5:36 am https://www.fiercebiotech.com/biotech/2-months-after-depression-fail-atai-lays-30-and-reviews-pipeline-again

Adaptimmune absorbs TCR² to extend cash runway and broaden T-cell pipeline March 6, 2023 4:40 am https://www.fiercebiotech.com/biotech/adaptimmune-absorbs-tcr2-extend-cash-runway-and-broaden-t-cell-pipeline

Big Pharma regained ‘mojo’ last year, but biotech valuations remain ‘precarious’: report March 3, 2023 6:07 am https://www.fiercebiotech.com/biotech/big-pharma-regained-mojo-last-year-biotech-valuations-remain-precarious-report